Neuroprotective actions of Glucagon-like peptide-1 in differentiated human neuroprogenitor cells

Journal of Neurochemistry

Volumn 123, Issue 6, 2012, Pages 919-931

  Velmurugan, Kalpana ^a   Bouchard, Ron ^a   Mahaffey, Gregory ^a   Pugazhenthi, Subbiah ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; apoptosis; CREB; glucagon like peptide 1; human neuroprogenitor cells; signal transduction

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 3; CASPASE 6; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; NEUROTROPHIN; RETINOIC ACID;

APOPTOSIS; ARTICLE; CELL POPULATION; CELL PROLIFERATION; COGNITION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL DIFFERENTIATION; CELLS, CULTURED; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; NEURAL PATHWAYS; NEURAL STEM CELLS; NEUROPROTECTIVE AGENTS; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 84870586474     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12036     Document Type: Article

References (48)

1. Abbas T., Faivre E., and, Holscher C., (2009) Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav. Brain Res. 205, 265-271.
2. Akter K., Lanza E. A., Martin S. A., Myronyuk N., Rua M., and, Raffa R. B., (2011) Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br. J. Clin. Pharmacol. 71, 365-376.
3. Campbell R. K., and, Miller S.,. (2009) New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy. Diabetes Educ. 35, 731-747.
4. Cao F., Hata R., Zhu P., Nakashiro K., and, Sakanaka M., (2010) Conditional deletion of Stat3 promotes neurogenesis and inhibits astrogliogenesis in neural stem cells. Biochem. Biophys. Res. Commun. 394, 843-847.
5. Chen B., and, Cepko C. L., (2009) HDAC4 regulates neuronal survival in normal and diseased retinas. Science 323, 256-259.
6. Dickson S. L., Shirazi R. H., Hansson C., Bergquist F., Nissbrandt H., and, Skibicka K. P., (2012) The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J. Neurosci. 32, 4812-4820.
7. Drucker D. J., (2006) The biology of incretin hormones. Cell Metab. 3, 153-165.
8. Frank D. A., and, Greenberg M. E., (1994) CREB: a mediator of long-term memory from mollusks to mammals. Cell 79, 5-8.
9. Gengler S., McClean P. L., McCurtin R., Gault V. A., and, Holscher C., (2010) Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging 265-276.
10. Gilman C. P., Perry T., Furukawa K., Grieg N. H., Egan J. M., and, Mattson M. P., (2003) Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J. Neurochem. 87, 1137-1144.
11. Graham R. K., Ehrnhoefer D. E., and, Hayden M. R., (2011) Caspase-6 and neurodegeneration. Trends Neurosci. 34, 646-656.
12. Hamilton A., Patterson S., Porter D., Gault V. A., and, Holscher C., (2011) Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J. Neurosci. Res. 89, 481-489.
13. Han W., and, Li C., (2010) Linking type 2 diabetes and Alzheimer's disease. Proc. Natl Acad. Sci. USA 107, 6557-6558.
14. Hardy J., (2006) A hundred years of Alzheimer's disease research. Neuron 52, 3-13.
15. Ho L., Qin W., Pompl P. N., et al,. (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 18, 902-904.
16. Holscher C., and, Li L., (2010) New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease? Neurobiol. Aging 31, 1495-1502.
17. Ioacara S., Guja C., Ionescu-Tirgoviste C., Fica S., Sabau S., Radu S., Micu A., and, Tiu C., (2011) Improvements in life expectancy in adult type 2 diabetes patients in the last six decades. Diabetes Res. Clin. Pract. 92, 400-404.
18. Irwin N., Gault V., and, Flatt P. R., (2010) Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? Expert Opin. Investig. Drugs 19, 1039-1048.
19. Jack C. R. Jr, Knopman D. S., Jagust W. J., Shaw L. M., Aisen P. S., Weiner M. W., Petersen R. C., and, Trojanowski J. Q., (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119-128.
20. Kallur T., Gisler R., Lindvall O., and, Kokaia Z., (2008) Pax6 promotes neurogenesis in human neural stem cells. Mol. Cell. Neurosci. 38, 616-628.
21. Li Y., Tweedie D., Mattson M. P., Holloway H. W., and, Greig N. H., (2010) Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J. Neurochem. 113, 1621-1631.
22. McClean P. L., Parthsarathy V., Faivre E., and, Holscher C., (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31, 6587-6594.
23. Migani P., Bartlett C., Dunlop S., Beazley L., and, Rodger J., (2009) Regional and cellular distribution of ephrin-B1 in adult mouse brain. Brain Res. 1247, 50-61.
24. Nikolic M., Dudek H., Kwon Y. T., Ramos Y. F., and, Tsai L. H., (1996) The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev. 10, 816-825.
25. Ott A., Stolk R., Harskamp F. V., Pols H., Hoffman A., and, Breteler M., (1999) Diabetes mellitus and the risk of dementia. The Rotterdam study. Neurology 53, 1937-1942.
26. Palmer A. M., (2011) Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. Trends Pharmacol. Sci. 32, 141-147.
27. Perry T., and, Greig N. H., (2002) The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. J. Alzheimers Dis. 4, 487-496.
28. Perry T., and, Greig N. H., (2005) Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr. Alzheimer Res. 2, 377-385.
29. Phillips H. S., Hains J. M., Armanini M., Laramee G. R., Johnson S. A., and, Winslow J. W., (1991) BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7, 695-702.
30. Pruunsild P., Sepp M., Orav E., Koppel I., and, Timmusk T., (2011) Identification of cis-elements and transcription factors regulating neuronal activity-dependent transcription of human BDNF gene. J. Neurosci. 31, 3295-3308.
31. Pugazhenthi S., Boras T., O'Connor D., Meintzer M. K., Heidenreich K. A., and, Reusch J. E., (1999a) Insulin-like growth factor I-mediated activation of the transcription factor cAMP response element-binding protein in PC12 cells. Involvement of p38 mitogen-activated protein kinase-mediated pathway. J. Biol. Chem. 274, 2829-2837.
32. Pugazhenthi S., Miller E., Sable C., Young P., Heidenreich K. A., Boxer L. M., and, Reusch J. E.-B., (1999b) Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element binding protein. J. Biol. Chem. 274, 27529-27535.
33. Pugazhenthi S., Nesterova A., Sable C., Heidenreich K., Boxer L., Heasley L., and, Reusch J., (2000) Akt/Protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 275, 10761-10766.
34. Pugazhenthi S., Nesterova A., Jambal P., Audesirk G., Kern M., Cabell L., Eves E., Rosner M. R., Boxer L. M., and, Reusch J. E., (2003) Oxidative stress-mediated down-regulation of bcl-2 promoter in hippocampal neurons. J. Neurochem. 84, 982-996.
35. Pugazhenthi S., Phansalkar K., Audesirk G., West A., and, Cabell L., (2006) Differential regulation of c-jun and CREB by acrolein and 4-hydroxynonenal. Free Radic. Biol. Med. 40, 21-34.
36. Pugazhenthi U., Velmurugan K., Tran A., Mahaffey G., and, Pugazhenthi S., (2010) Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients. Diabetologia 53, 2357-2368.
37. Pugazhenthi S., Wang M., Pham S., Sze C. I., and, Eckman C. B., (2011a) Downregulation of CREB expression in Alzheimer's brain and in Abeta-treated rat hippocampal neurons. Mol. Neurodegener. 6, 60.
38. Pugazhenthi S., Nair S., Velmurugan K., Liang Q., Mahalingam R., Cohrs R. J., Nagel M. A., and, Gilden D., (2011b) Varicella-zoster virus infection of differentiated human neural stem cells. J. Virol. 85, 6678-6686.
39. Querfurth H. W., and, LaFerla F. M., (2010) Alzheimer's disease. N. Engl. J. Med. 362, 329-344.
40. Rissman R. A., Poon W. W., Blurton-Jones M., Oddo S., Torp R., Vitek M. P., LaFerla F. M., Rohn T. T., and, Cotman C. W., (2004) Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J. Clin. Invest. 114, 121-130.
41. Rohn T. T., Vyas V., Hernandez-Estrada T., Nichol K. E., Christie L. A., and, Head E., (2008) Lack of pathology in a triple transgenic mouse model of Alzheimer's disease after overexpression of the anti-apoptotic protein Bcl-2. J. Neurosci. 28, 3051-3059.
42. Roth K. A., (2001) Caspases, apoptosis, and Alzheimer disease: causation, correlation, and confusion. J. Neuropathol. Exp. Neurol. 60, 829-838.
43. Ryan D. A., Narrow W. C., Federoff H. J., and, Bowers W. J., (2010) An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies. J. Neurosci. Methods 190, 171-179.
44. Sarkar S. A., Gunter J., Bouchard R., Reusch J. E., Wiseman A., Gill R. G., Hutton J. C., and, Pugazhenthi S., (2007) Dominant negative mutant forms of the cAMP response element binding protein induce apoptosis and decrease the anti-apoptotic action of growth factors in human islets. Diabetologia 50, 1649-1659.
45. Takeda S., Sato N., Uchio-Yamada K., Sawada K., Kunieda T., Takeuchi D., Kurinami H., Shinohara M., Rakugi H., and, Morishita R., (2010) Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc. Natl Acad. Sci. USA 107, 7036-7041.
46. Valente T., Gella A., Fernandez-Busquets X., Unzeta M., and, Durany N., (2010) Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol. Dis. 37, 67-76.
47. Velmurugan K., Balamurugan A. N., Loganathan G., Ahmad A., Hering B. J., and, Pugazhenthi S., (2012) Antiapoptotic Actions of Exendin-4 against Hypoxia and Cytokines Are Augmented by CREB. Endocrinology 1116-1128.
48. Yamamoto-sasaki M., Ozawa H., Saito T., Rosler M., and, Riederer P., (1999) Impaired phosphrylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimers type. Brain Res. 824, 300-303.